Luke Webb, MD
Internal Medicine · Colorado Springs, CONPI 1932161916
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $223,550 of the $287,287 with a category attached, or 77.8%. AstraZeneca accounts for 83.2% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $69,182 and has fallen 73.0% since, to $18,673 in 2025. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $358.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$239K
- Amgen$35K
- Optinose US, Inc.$3K
- Sanofi$2K
- Grifols USA, LLC$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- plus $6K from 31 others
Across 252 payments — averaging $7044.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$485K
- GSK$425K
- Pfizer$319K
- Regeneron$191K
- Eli Lilly$177K
- AstraZeneca$87K
- plus $92K from 5 others
What the payments were for
- Consulting fees$20,8267%
- Speaking & faculty fees$223,55078%
- Travel & lodging$25,5819%
- Food & beverage$17,1486%
- Education$1830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 350 | $239,029 |
| Amgen(2 entities) | 43 | $34,911 |
| Optinose US, Inc. | 14 | $2,809 |
| Sanofi | 52 | $1,925 |
| Grifols USA, LLC | 19 | $1,514 |
| Takeda Pharmaceuticals U.S.A., Inc. | 88 | $1,366 |
| GSK | 57 | $910 |
| Genentech USA, Inc. | 28 | $712 |
| CSL Behring | 27 | $665 |
| Eli Lilly | 1 | $450 |
| Biocryst US Sales Co., LLC | 10 | $432 |
| Regeneron Healthcare Solutions, Inc. | 22 | $401 |
| Novartis | 20 | $393 |
| Pharming Healthcare, Inc. | 8 | $326 |
| Sanofi-aventis U.S. LLC | 3 | $231 |
| Pfizer | 11 | $167 |
| Kaleo, Inc. | 7 | $164 |
| AbbVie | 4 | $97 |
| Teva Pharmaceuticals USA, Inc. | 5 | $93 |
| Boehringer Ingelheim | 5 | $91 |
| QOL Medical, LLC | 5 | $82 |
| Blueprint Medicines Corporation | 2 | $62 |
| Shire North American Group Inc | 3 | $60 |
| Ionis Pharmaceuticals, Inc. | 2 | $53 |
| ADMA Biomanufacturing LLC | 2 | $52 |
| Incyte Corporation | 1 | $40 |
| Octapharma USA, Inc. | 2 | $37 |
| Biocryst Pharmaceuticals, Inc. | 2 | $35 |
| Greer Laboratories, Inc. | 1 | $33 |
| Aimmune Therapeutics, Inc. | 1 | $26 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $25 |
| Phadia US Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| GC Biopharma USA, Inc. | 1 | $18 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Merck | 1 | $16 |
| Organon | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,287 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 41 | $157,646 |
| TezspireTezepelumab-Ekko | 34 | $141,625 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $42,244 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $17,570 |
| Spiriva RespimatTiotropium Bromide | 13 | $11,810 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,332 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $9,231 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 20 | $4,173 |
| Epinephrine | 16 | $4,138 |
| Advair HfaFluticasone Propion/Salmeterol | 13 | $4,071 |
| Ipratropium Bromide | 39 | $1,744 |
| Azelastine Hcl | 36 | $1,549 |
| Montelukast Sodium | 152 | $1,485 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $1,274 |
| Fluticasone Propionate | 34 | $601 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $239,029 | $168,52782 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $910 | $51,47568 claims |
| Boehringer IngelheimSpiriva Respimat | $91 | $11,81013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Colorado Springs
- Samuel PiedadColorado Springs$154K
- Munni SelagamsettyColorado Springs$55K
- Sridhar ReddyColorado Springs$21K
- Quinn HalversonColorado Springs$11K
- Pankaj NashikkarColorado Springs$10K
- Elizabeth CruzColorado Springs$9K
- Tayler SandersColorado Springs$7K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.